Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Maze Therapeutics, Inc. (MAZE)
USD29.05
-0.83 (-2.79%)
US NASDAQ Healthcare Biotechnology
Address
171 Oyster Point Blvd 94080
South San Francisco, CA, US
South San Francisco, CA, US
CEO
Jason Coloma
Website
mazetx.com
IPO
2025-01-31
CIK 1842295 ISIN US5787841007
Description
Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of kidney and metabolic diseases in the United States. Its lead programs include MZE829, an oral small molecule inhibitor of apolipoprotein L1, or APOL1, which is in phase II clinical trial for the treatment of patients with APOL1 kidney disease; and MZE782, an oral small molecule inhibitor that is in phase II ready clinical trial for the treatment of phenylketonuria and chronic kidney disease. The company also develops MZE001, an investigational oral small molecule inhibitor of muscle-specific glycogen synthase clinical program for the treatment of Pompe disease. It has a license agreement with Trace Neuroscience, Inc. to discovery research program targets UNC13A; the Shionogi & Co., Ltd to research, develop, manufacture, and commercialize MZE001; and Neurocrine Biosciences, Inc. to discover research program that targets ATXN2. The company was formerly known as Modulus Therapeutics, Inc. and changed its name to Maze Therapeutics, Inc. in September 2018. The company was incorporated in 2017 and is based in South San Francisco, California.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD29.05
-0.83 (-2.79%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
744.4K
Beta
2.26
Float Shares
15.95M
Free Float %
28.9%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +1.02% | +1.30% | -5.98% | -43.97% | -19.03% | -37.77% | +161.46% | +61.63% | +61.63% | +61.63% | +61.63% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (6 ratings, all time)
Buy
Price Targets & DCF
Current price
29.05
Low
46.00
+58.4%
Consensus
59.43
+104.6%
Median
55.00
+89.4%
High
97.00
+234.0%
DCF (Unlevered)
3.86
-86.7%
DCF (Levered)
3.86
-86.7%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 11 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | 1 |
64.00
+120.3%
|
| Last Quarter | 3 |
76.33
+162.8%
|
| Last Year | 11 |
51.36
+76.8%
|
| All Time | 11 |
51.36
+76.8%
|
Quality scores
Altman Z-Score
9.26
Safe zone
Piotroski F-Score
2 / 9
Weak
MOAT Score
0 / 10
No MOAT
Composite Rating
C
Overall Score
2 / 5
Medium
DCF Score
3 / 5
Medium
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
3 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
2 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%-100.0%
-
EPS growth Biotechnology: +29.7%-4,020.3% Q1'26: +39.9% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%—
-
EBIT margin Biotechnology: +0.0%—
-
ROIC Biotechnology: -16.1%-393.1% Q1'26: +0.0% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%-1.9% ★ Q1'26: +23.1% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.17× Q1'26: -0.21× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 8 Rev. Ana. 7 EPS Ana. |
Dec 2027 8 Rev. Ana. 7 EPS Ana. |
Dec 2028 8 Rev. Ana. 6 EPS Ana. |
Dec 2029 7 Rev. Ana. 4 EPS Ana. |
Dec 2030 7 Rev. Ana. 2 EPS Ana. |
|---|---|---|---|---|---|---|---|
| Revenue |
167.50M
est: 167.67M (-0.1%)
|
—
est: 3.13M (-100.0%)
|
12.50M
11.74M – 13.26M
+300.0% YoY
|
6.22M
5.43M – 7.00M
-50.3% YoY
|
4.12M
3.87M – 4.37M
-33.7% YoY
|
42.65M
40.05M – 45.24M
+935.0% YoY
|
208.30M
195.63M – 220.96M
+388.4% YoY
|
| EBITDA |
60.88M
est: 140.99M (-56.8%)
|
-140.50M
est: 2.63M (-5,446.7%)
|
10.51M
9.87M – 11.15M
+300.0% YoY
|
5.23M
4.57M – 5.89M
-50.3% YoY
|
3.46M
3.25M – 3.68M
-33.7% YoY
|
35.86M
33.68M – 38.04M
+935.0% YoY
|
175.15M
164.50M – 185.80M
+388.4% YoY
|
| EBIT |
57.59M
est: 140.16M (-58.9%)
|
-142.90M
est: 2.61M (-5,570.2%)
|
10.45M
9.81M – 11.08M
+300.0% YoY
|
5.20M
4.54M – 5.85M
-50.3% YoY
|
3.44M
3.23M – 3.65M
-33.7% YoY
|
35.65M
33.48M – 37.82M
+935.0% YoY
|
174.13M
163.54M – 184.71M
+388.4% YoY
|
| Net Income |
52.23M
est: -338.76M (+115.4%)
|
-131.12M
est: -131.12M (+0.0%)
|
-123.63M
-143.64M – -103.61M
+5.7% YoY
|
-187.82M
-203.56M – -107.21M
-51.9% YoY
|
-177.99M
-240.16M – -115.81M
+5.2% YoY
|
-163.47M
-176.39M – -150.55M
+8.2% YoY
|
-99.01M
-106.83M – -91.18M
+39.4% YoY
|
| SGA |
26.42M
est: 132.36M (-80.0%)
|
34.45M
est: 2.47M (+1,296.5%)
|
9.87M
9.27M – 10.47M
+300.0% YoY
|
4.91M
4.29M – 5.53M
-50.3% YoY
|
3.25M
3.05M – 3.45M
-33.7% YoY
|
33.67M
31.62M – 35.71M
+935.0% YoY
|
164.44M
154.44M – 174.44M
+388.4% YoY
|
| EPS |
0.08
est: -7.88 (+101.0%)
|
-3.05
est: -3.12 (+2.2%)
|
-2.84
-3.34 – -2.41
+9.0% YoY
|
-3.27
-4.74 – -2.49
-15.3% YoY
|
-3.68
-5.59 – -2.69
-12.4% YoY
|
-3.80
-4.10 – -3.50
-3.3% YoY
|
-2.30
-2.49 – -2.12
+39.4% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-12 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-11 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-08 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-07 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-06 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-05 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-04 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-01 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-30 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-29 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-28 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-27 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-24 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-23 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-22 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-21 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-20 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-17 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-16 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-253.29M
OE per share TTM
-5.59
Owner's Yield
-18.23%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
78.4%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
57
Total invested
370.13M
Insider transactions (90d)
3
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
57
-87 vs prev Q
New positions
15
Closed positions
103
Increased
36
Reduced
9
Put/Call ratio
0.69
Calls held
19.5K
Puts held
13.4K
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | MASS GENERAL BRIGHAM, INC | 240.0K +240.0K (+100.0%) | 9.94B +9.9B (+100.0%) | 0.52% +0.524 pp | 1.23% +1.228 pp | USD41.43 +0.0% | 1 qtrs NEW |
| 2 | FRAZIER LIFE SCIENCES MANAGEMENT, L.P. | 4.57M +— (+0.0%) | 189.22M +70.8M (+59.8%) | 9.98% -0.439 pp | 5.08% +1.534 pp | USD11.13 +272.2% | 4 qtrs — |
| 3 | TRV GP IV, LLC | 4.47M -1.6M (-26.3%) | 185.36M +27.9M (+17.7%) | 9.77% -4.079 pp | 72.65% +15.163 pp | USD11.01 +276.3% | 4 qtrs — |
| 4 | DEEP TRACK CAPITAL, LP | 4.25M +297.5K (+7.5%) | 175.93M +73.5M (+71.8%) | 9.28% +0.271 pp | 3.14% +0.279 pp | USD13.34 +210.6% | 4 qtrs — |
| 5 | ARCH VENTURE MANAGEMENT, LLC | 4.12M +— (+0.0%) | 170.69M +63.9M (+59.8%) | 9.00% -0.396 pp | 26.19% +4.495 pp | USD11.01 +276.3% | 4 qtrs — |
| 6 | JANUS HENDERSON GROUP PLC | 3.14M +2.4M (+318.0%) | 130.20M +110.7M (+568.1%) | 6.86% +5.150 pp | 0.06% +0.049 pp | USD34.19 +21.2% | 4 qtrs — |
| 7 | BLACKROCK, INC. | 2.29M +971.1K (+73.8%) | 94.76M +60.6M (+177.7%) | 5.00% +1.995 pp | 0.00% +0.001 pp | USD28.52 +45.3% | 4 qtrs — |
| 8 | AH CAPITAL MANAGEMENT, L.L.C. | 1.70M +— (+0.0%) | 70.52M +26.4M (+59.8%) | 3.72% -0.164 pp | 4.46% +1.300 pp | USD11.01 +276.3% | 4 qtrs — |
| 9 | VANGUARD GROUP INC | 1.70M +362.1K (+27.1%) | 70.31M +35.7M (+103.1%) | 3.71% +0.663 pp | 0.00% +0.001 pp | USD25.55 +62.2% | 4 qtrs — |
| 10 | VR ADVISER, LLC | 1.55M +317.8K (+25.8%) | 64.16M +32.2M (+101.0%) | 3.38% +0.576 pp | 3.17% +1.373 pp | USD29.11 +42.3% | 2 qtrs — |
| 11 | ALPHABET INC. | 1.39M -1.0M (-42.4%) | 57.53M -5.0M (-8.0%) | 3.03% -2.468 pp | 2.23% -0.367 pp | USD11.01 +276.3% | 4 qtrs — |
| 12 | GENERAL CATALYST GROUP MANAGEMENT, LLC | 1.04M +— (+0.0%) | 42.92M +16.1M (+59.8%) | 2.26% -0.100 pp | 19.35% +18.471 pp | USD11.01 +276.3% | 4 qtrs — |
| 13 | WOODLINE PARTNERS LP | 1.04M +— (+0.0%) | 42.89M +16.0M (+59.8%) | 2.26% -0.100 pp | 0.17% +0.040 pp | USD12.39 +234.4% | 4 qtrs — |
| 14 | TRV GP V, LLC | 950.8K +— (+0.0%) | 39.39M +14.7M (+59.8%) | 2.08% -0.091 pp | 9.18% +2.204 pp | USD11.01 +276.3% | 4 qtrs — |
| 15 | LOGOS GLOBAL MANAGEMENT LP | 950.0K -277.3K (-22.6%) | 39.36M +7.5M (+23.7%) | 2.08% -0.724 pp | 2.38% -0.474 pp | USD18.49 +124.1% | 4 qtrs — |
| 16 | BELLEVUE GROUP AG | 887.7K +887.7K (+100.0%) | 36.78M +36.8M (+100.0%) | 1.94% +1.939 pp | 0.70% +0.697 pp | USD41.43 +0.0% | 1 qtrs NEW |
| 17 | MARSHALL WACE, LLP | 847.5K +69.8K (+9.0%) | 35.11M +14.9M (+74.1%) | 1.85% +0.078 pp | 0.03% +0.012 pp | USD26.86 +54.2% | 4 qtrs — |
| 18 | ARROWMARK COLORADO HOLDINGS LLC | 767.4K +222.3K (+40.8%) | 31.79M +17.7M (+124.9%) | 1.68% +0.433 pp | 0.70% +0.437 pp | USD30.42 +36.2% | 2 qtrs — |
| 19 | CASDIN CAPITAL, LLC | 758.9K +— (+0.0%) | 31.44M +11.8M (+59.8%) | 1.66% -0.073 pp | 1.95% +0.312 pp | USD11.01 +276.3% | 4 qtrs — |
| 20 | FMR LLC | 728.6K +73.0K (+11.1%) | 30.19M +13.2M (+77.6%) | 1.59% +0.097 pp | 0.00% +0.001 pp | USD16.13 +156.9% | 4 qtrs — |
| 21 | IKARIAN CAPITAL, LLC | 644.7K -96.1K (-13.0%) | 26.71M +7.5M (+39.0%) | 1.41% -0.281 pp | 2.09% +0.146 pp | USD20.64 +100.7% | 4 qtrs — |
| 22 | CALIGAN PARTNERS LP | 550.2K +550.2K (+100.0%) | 22.79M +22.8M (+100.0%) | 1.20% +1.202 pp | 1.88% +1.876 pp | USD41.43 +0.0% | 1 qtrs NEW |
| 23 | STATE STREET CORP | 533.0K +148.3K (+38.6%) | 22.08M +12.1M (+121.4%) | 1.16% +0.287 pp | 0.00% +0.000 pp | USD26.38 +57.1% | 4 qtrs — |
| 24 | GEODE CAPITAL MANAGEMENT, LLC | 527.3K +53.7K (+11.3%) | 21.85M +9.6M (+77.9%) | 1.15% +0.072 pp | 0.00% +0.001 pp | USD21.01 +97.2% | 4 qtrs — |
| 25 | FORESITE CAPITAL MANAGEMENT IV, LLC | 522.7K +— (+0.0%) | 21.65M +8.1M (+59.8%) | 1.14% -0.050 pp | 9.43% +2.005 pp | USD11.01 +276.3% | 4 qtrs — |
| 26 | — | 490.0K +490.0K (+100.0%) | 20.30M +20.3M (+100.0%) | 1.07% +1.070 pp | 8.60% +8.603 pp | USD41.43 +0.0% | 1 qtrs NEW |
| 27 | BESSEMER GROUP INC | 481.8K +— (+0.0%) | 19.96M +7.5M (+59.8%) | 1.05% -0.046 pp | 0.03% +0.012 pp | USD11.01 +276.3% | 4 qtrs — |
| 28 | MATRIX CAPITAL MANAGEMENT COMPANY, LP | 480.0K -1.2M (-71.0%) | 19.89M -23.0M (-53.6%) | 1.05% -2.723 pp | 34.52% -5.656 pp | USD11.01 +276.3% | 4 qtrs — |
| 29 | HHLR ADVISORS, LTD. | 457.5K +— (+0.0%) | 18.96M +7.1M (+59.8%) | 1.00% -0.044 pp | 0.61% +0.321 pp | USD11.01 +276.3% | 4 qtrs — |
| 30 | CITADEL ADVISORS LLC | 448.2K +448.2K (+100.0%) | 18.57M +18.6M (+100.0%) | 0.98% +0.979 pp | 0.00% +0.003 pp | USD41.43 +0.0% | 1 qtrs NEW |
| 31 | BOOTHBAY FUND MANAGEMENT, LLC | 409.4K +57.5K (+16.3%) | 16.96M +7.8M (+85.9%) | 0.89% +0.092 pp | 0.25% +0.120 pp | USD25.35 +63.4% | 4 qtrs — |
| 32 | DRIEHAUS CAPITAL MANAGEMENT LLC | 378.0K +— (+0.0%) | 15.66M +5.9M (+59.8%) | 0.83% -0.036 pp | 0.11% +0.036 pp | USD18.50 +123.9% | 4 qtrs — |
| 33 | EVENTIDE ASSET MANAGEMENT, LLC | 324.0K +324.0K (+100.0%) | 13.43M +13.4M (+100.0%) | 0.71% +0.708 pp | 0.21% +0.210 pp | USD41.43 +0.0% | 1 qtrs NEW |
| 34 | WASHINGTON UNIVERSITY | 280.8K +70.1K (+33.3%) | 11.63M +6.2M (+113.0%) | 0.61% +0.133 pp | 5.88% +2.821 pp | USD29.80 +39.0% | 2 qtrs — |
| 35 | MORGAN STANLEY | 258.1K +45.3K (+21.3%) | 10.69M +5.2M (+93.8%) | 0.56% +0.079 pp | 0.00% +0.000 pp | USD26.85 +54.3% | 4 qtrs — |
| 36 | PARKMAN HEALTHCARE PARTNERS LLC | 209.3K +9.3K (+4.6%) | 8.67M +3.5M (+67.2%) | 0.46% +0.001 pp | 0.83% +0.284 pp | USD26.62 +55.6% | 2 qtrs — |
| 37 | BALYASNY ASSET MANAGEMENT L.P. | 199.2K -234.5K (-54.1%) | 8.25M -3.0M (-26.6%) | 0.44% -0.554 pp | 0.01% -0.004 pp | USD25.93 +59.8% | 2 qtrs — |
| 38 | ALYESKA INVESTMENT GROUP, L.P. | 196.1K +71.1K (+56.9%) | 8.13M +4.9M (+150.7%) | 0.43% +0.143 pp | 0.02% +0.013 pp | USD22.04 +88.0% | 4 qtrs — |
| 39 | ENSIGN PEAK ADVISORS, INC | 185.8K +115.1K (+162.9%) | 7.70M +5.9M (+320.1%) | 0.41% +0.245 pp | 0.01% +0.011 pp | USD34.17 +21.2% | 3 qtrs — |
| 40 | ADAR1 CAPITAL MANAGEMENT, LLC | 179.5K +153.5K (+589.3%) | 7.44M +6.8M (+1,001.4%) | 0.39% +0.333 pp | 0.55% +0.483 pp | USD39.18 +5.7% | 2 qtrs — |
| 41 | NORTHERN TRUST CORP | 176.3K -631.0 (-0.4%) | 7.30M +2.7M (+59.2%) | 0.39% -0.018 pp | 0.00% +0.000 pp | USD18.82 +120.1% | 4 qtrs — |
| 42 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 176.0K +8.0K (+4.8%) | 7.29M +2.9M (+67.4%) | 0.38% +0.001 pp | 0.00% +0.000 pp | USD20.29 +104.2% | 4 qtrs — |
| 43 | TCG CROSSOVER MANAGEMENT, LLC | 173.8K +173.8K (+100.0%) | 7.20M +7.2M (+100.0%) | 0.38% +0.380 pp | 0.24% +0.238 pp | USD41.43 +0.0% | 1 qtrs NEW |
| 44 | HIGHVISTA STRATEGIES LLC | 170.4K +170.4K (+100.0%) | 7.06M +7.1M (+100.0%) | 0.37% +0.372 pp | 1.82% +1.818 pp | USD41.43 +0.0% | 1 qtrs NEW |
| 45 | MILLENNIUM MANAGEMENT LLC | 154.5K +154.5K (+100.0%) | 6.40M +6.4M (+100.0%) | 0.34% +0.337 pp | 0.00% +0.003 pp | USD41.43 +0.0% | 1 qtrs NEW |
| 46 | INVESCO LTD. | 134.0K +2.0K (+1.5%) | 5.55M +2.1M (+62.2%) | 0.29% -0.008 pp | 0.00% +0.000 pp | USD24.11 +71.8% | 4 qtrs — |
| 47 | STEMPOINT CAPITAL LP | 125.9K +125.9K (+100.0%) | 5.22M +5.2M (+100.0%) | 0.28% +0.275 pp | 0.89% +0.894 pp | USD41.43 +0.0% | 1 qtrs NEW |
| 48 | FREESTONE GROVE PARTNERS LP | 118.9K +118.9K (+100.0%) | 4.93M +4.9M (+100.0%) | 0.26% +0.260 pp | 0.04% +0.036 pp | USD41.43 +0.0% | 1 qtrs NEW |
| 49 | PRICE T ROWE ASSOCIATES INC /MD/ | 115.7K +105.2K (+1,004.7%) | 4.79M +4.5M (+1,662.5%) | 0.25% +0.229 pp | 0.00% +0.001 pp | USD40.03 +3.5% | 2 qtrs — |
| 50 | GOLDMAN SACHS GROUP INC | 114.5K +114.5K (+100.0%) | 4.74M +4.7M (+100.0%) | 0.25% +0.250 pp | 0.00% +0.001 pp | USD41.43 +0.0% | 1 qtrs NEW |
| 51 | INTEGRAL HEALTH ASSET MANAGEMENT, LLC | 100.0K +100.0K (+100.0%) | 4.14M +4.1M (+100.0%) | 0.22% +0.218 pp | 0.21% +0.206 pp | USD41.43 +0.0% | 1 qtrs NEW |
| 52 | AMERIPRISE FINANCIAL INC | 96.7K +96.7K (+100.0%) | 4.01M +4.0M (+100.0%) | 0.21% +0.211 pp | 0.00% +0.001 pp | USD41.43 +0.0% | 1 qtrs NEW |
| 53 | FORESITE CAPITAL MANAGEMENT V, LLC | 86.3K +— (+0.0%) | 3.58M +1.3M (+59.8%) | 0.19% -0.008 pp | 2.17% +0.117 pp | USD11.01 +276.3% | 4 qtrs — |
| 54 | BIOIMPACT CAPITAL LLC | 81.1K +81.1K (+100.0%) | 3.36M +3.4M (+100.0%) | 0.18% +0.177 pp | 0.38% +0.385 pp | USD41.43 +0.0% | 1 qtrs NEW |
| 55 | SPHERA FUNDS MANAGEMENT LTD. | 71.8K -82.5K (-53.5%) | 2.98M -1.0M (-25.6%) | 0.16% -0.195 pp | 0.58% -0.269 pp | USD11.01 +276.3% | 4 qtrs — |
| 56 | SUMMITTX CAPITAL, L.P. | 69.6K +69.6K (+100.0%) | 2.88M +2.9M (+100.0%) | 0.15% +0.152 pp | 0.09% +0.087 pp | USD41.43 +0.0% | 1 qtrs NEW |
| 57 | RAYMOND JAMES FINANCIAL INC | 67.7K +67.7K (+100.0%) | 2.81M +2.8M (+100.0%) | 0.15% +0.148 pp | 0.00% +0.001 pp | USD41.43 +0.0% | 1 qtrs NEW |
| 58 | WELLINGTON MANAGEMENT GROUP LLP | 61.2K +61.2K (+100.0%) | 2.54M +2.5M (+100.0%) | 0.13% +0.134 pp | 0.00% +0.000 pp | USD41.43 +0.0% | 1 qtrs NEW |
| 59 | BANK OF NEW YORK MELLON CORP | 60.4K +15.2K (+33.6%) | 2.50M +1.3M (+113.4%) | 0.13% +0.029 pp | 0.00% +0.000 pp | USD24.60 +68.4% | 4 qtrs — |
| 60 | ADVISOR GROUP HOLDINGS, INC. | 59.8K +29.2K (+95.8%) | 2.48M +1.7M (+212.8%) | 0.13% +0.061 pp | 0.00% +0.003 pp | USD33.50 +23.7% | 3 qtrs — |
| 61 | NUVEEN, LLC | 57.3K +27.0K (+88.9%) | 2.37M +1.6M (+201.9%) | 0.13% +0.056 pp | 0.00% +0.000 pp | USD30.26 +36.9% | 4 qtrs — |
| 62 | FRANKLIN RESOURCES INC | 55.2K +37.0K (+203.5%) | 2.29M +1.8M (+384.9%) | 0.12% +0.079 pp | 0.00% +0.000 pp | USD36.32 +14.1% | 2 qtrs — |
| 63 | TREXQUANT INVESTMENT LP | 52.5K +52.5K (+100.0%) | 2.17M +2.2M (+100.0%) | 0.11% +0.115 pp | 0.02% +0.019 pp | USD41.43 +0.0% | 1 qtrs NEW |
| 64 | SEVEN GRAND MANAGERS, LLC | 50.0K +50.0K (+100.0%) | 2.07M +2.1M (+100.0%) | 0.11% +0.109 pp | 0.16% +0.158 pp | USD41.43 +0.0% | 1 qtrs NEW |
| 65 | SCHONFELD STRATEGIC ADVISORS LLC | 48.2K -65.8K (-57.7%) | 2.00M -960.4K (-32.5%) | 0.11% -0.155 pp | 0.01% -0.008 pp | USD25.93 +59.8% | 2 qtrs — |
| 66 | BARCLAYS PLC | 39.5K +12.0K (+43.6%) | 1.64M +923.3K (+129.4%) | 0.09% +0.024 pp | 0.00% +0.000 pp | USD25.11 +65.0% | 4 qtrs — |
| 67 | D. E. SHAW & CO., INC. | 33.7K +33.7K (+100.0%) | 1.40M +1.4M (+100.0%) | 0.07% +0.074 pp | 0.00% +0.001 pp | USD41.43 +0.0% | 1 qtrs NEW |
| 68 | ALLIANCEBERNSTEIN L.P. | 33.2K -26.9K (-44.7%) | 1.38M -182.1K (-11.7%) | 0.07% -0.065 pp | 0.00% 0.000 pp | USD18.04 +129.7% | 4 qtrs — |
| 69 | XTX TOPCO LTD | 33.0K +6.2K (+22.9%) | 1.37M +671.4K (+96.4%) | 0.07% +0.011 pp | 0.04% 0.000 pp | USD28.82 +43.8% | 2 qtrs — |
| 70 | MIRAE ASSET GLOBAL ETFS HOLDINGS LTD. | 31.3K +22.2K (+244.7%) | 1.30M +1.1M (+450.8%) | 0.07% +0.048 pp | 0.00% +0.002 pp | USD34.60 +19.7% | 4 qtrs — |
| 71 | CINCTIVE CAPITAL MANAGEMENT LP | 29.1K +29.1K (+100.0%) | 1.21M +1.2M (+100.0%) | 0.06% +0.064 pp | 0.07% +0.065 pp | USD41.43 +0.0% | 1 qtrs NEW |
| 72 | UBS GROUP AG | 28.7K +905.0 (+3.3%) | 1.19M +468.3K (+65.0%) | 0.06% -0.001 pp | 0.00% +0.000 pp | USD11.97 +246.1% | 4 qtrs — |
| 73 | AQR CAPITAL MANAGEMENT LLC | 27.4K -176.0 (-0.6%) | 1.14M +420.7K (+58.8%) | 0.06% -0.003 pp | 0.00% +0.000 pp | USD12.34 +235.7% | 3 qtrs — |
| 74 | RENAISSANCE TECHNOLOGIES LLC | 27.1K -59.0K (-68.5%) | 1.12M -1.1M (-49.7%) | 0.06% -0.137 pp | 0.00% -0.001 pp | USD25.93 +59.8% | 2 qtrs — |
| 75 | TUDOR INVESTMENT CORP ET AL | 24.1K +24.1K (+100.0%) | 996.8K +996.8K (+100.0%) | 0.05% +0.053 pp | 0.00% +0.002 pp | USD41.43 +0.0% | 1 qtrs NEW |
| 76 | WELLS FARGO & COMPANY/MN | 24.0K +9.2K (+62.4%) | 994.7K +611.4K (+159.6%) | 0.05% +0.019 pp | 0.00% +0.000 pp | USD28.45 +45.6% | 4 qtrs — |
| 77 | RHUMBLINE ADVISERS | 23.7K +2.8K (+13.2%) | 983.2K +439.4K (+80.8%) | 0.05% +0.004 pp | 0.00% +0.000 pp | USD22.91 +80.8% | 4 qtrs — |
| 78 | GILDER GAGNON HOWE & CO LLC | 23.3K +23.3K (+100.0%) | 964.6K +964.6K (+100.0%) | 0.05% +0.051 pp | 0.01% +0.010 pp | USD41.43 +0.0% | 1 qtrs NEW |
| 79 | RUSSELL INVESTMENTS GROUP, LTD. | 22.5K +20.6K (+1,082.2%) | 934.0K +884.6K (+1,788.9%) | 0.05% +0.045 pp | 0.00% +0.001 pp | USD40.01 +3.5% | 3 qtrs — |
| 80 | VERITION FUND MANAGEMENT LLC | 22.5K +22.5K (+100.0%) | 932.7K +932.7K (+100.0%) | 0.05% +0.049 pp | 0.00% +0.004 pp | USD41.43 +0.0% | 1 qtrs NEW |
| 81 | AMERICAN CENTURY COMPANIES INC | 21.5K +21.5K (+100.0%) | 891.1K +891.1K (+100.0%) | 0.05% +0.047 pp | 0.00% +0.000 pp | USD41.43 +0.0% | 1 qtrs NEW |
| 82 | JPMORGAN CHASE & CO | 20.0K +12.1K (+153.6%) | 828.9K +624.3K (+305.2%) | 0.04% +0.026 pp | 0.00% +0.000 pp | USD32.06 +29.2% | 4 qtrs — |
| 83 | ACUTA CAPITAL PARTNERS, LLC | 20.0K +20.0K (+100.0%) | 828.6K +828.6K (+100.0%) | 0.04% +0.044 pp | 0.56% +0.563 pp | USD41.43 +0.0% | 1 qtrs NEW |
| 84 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 19.4K +19.4K (+100.0%) | 803.7K +803.7K (+100.0%) | 0.04% +0.042 pp | 0.00% +0.000 pp | USD41.43 +0.0% | 1 qtrs NEW |
| 85 | BANK OF AMERICA CORP /DE/ | 18.4K +8.8K (+92.0%) | 761.5K +513.3K (+206.8%) | 0.04% +0.018 pp | 0.00% +0.000 pp | USD28.76 +44.1% | 4 qtrs — |
| 86 | DEUTSCHE BANK AG\ | 15.5K +6.6K (+74.7%) | 643.1K +412.7K (+179.1%) | 0.03% +0.014 pp | 0.00% +0.000 pp | USD24.02 +72.5% | 4 qtrs — |
| 87 | LOS ANGELES CAPITAL MANAGEMENT LLC | 19.1K +19.1K (+100.0%) | 634.5K +634.5K (+100.0%) | 0.04% +0.042 pp | 0.00% +0.002 pp | USD41.43 +0.0% | 1 qtrs NEW |
| 88 | TWO SIGMA ADVISERS, LP | 14.8K +14.8K (+100.0%) | 613.2K +613.2K (+100.0%) | 0.03% +0.032 pp | 0.00% +0.001 pp | USD41.43 +0.0% | 1 qtrs NEW |
| 89 | METLIFE INVESTMENT MANAGEMENT, LLC | 11.8K +— (+0.0%) | 488.9K +182.9K (+59.8%) | 0.03% -0.001 pp | 0.00% +0.001 pp | USD25.93 +59.8% | 2 qtrs — |
| 90 | CHINA UNIVERSAL ASSET MANAGEMENT CO., LTD. | 11.4K +9.4K (+472.1%) | 474.0K +422.1K (+814.0%) | 0.03% +0.020 pp | 0.04% +0.032 pp | USD38.72 +7.0% | 2 qtrs — |
| 91 | CITIGROUP INC | 11.3K +11.0K (+4,082.9%) | 466.2K +459.2K (+6,582.5%) | 0.02% +0.024 pp | 0.00% +0.000 pp | USD40.72 +1.7% | 4 qtrs — |
| 92 | STRS OHIO | 11.2K -6.7K (-37.4%) | 464.0K -131.0 (0.0%) | 0.02% -0.016 pp | 0.00% +0.000 pp | USD12.23 +238.8% | 4 qtrs — |
| 93 | FALCON WEALTH PLANNING | 10.0K +10.0K (+100.0%) | 415.5K +415.5K (+100.0%) | 0.02% +0.022 pp | 0.04% +0.035 pp | USD41.43 +0.0% | 1 qtrs NEW |
| 94 | PEAK6 LLC | 9.2K +9.2K (+100.0%) | 381.2K +381.2K (+100.0%) | 0.02% +0.020 pp | 0.00% +0.001 pp | USD41.43 +0.0% | 1 qtrs NEW |
| 95 | SG AMERICAS SECURITIES, LLC | 8.5K +3.5K (+69.4%) | 352.0K +222.0K (+170.8%) | 0.02% +0.007 pp | 0.00% +0.000 pp | USD32.28 +28.3% | 2 qtrs — |
| 96 | TWO SIGMA INVESTMENTS, LP | 7.2K -3.9K (-35.0%) | 300.2K +11.0K (+3.8%) | 0.02% -0.010 pp | 0.00% +0.000 pp | USD25.93 +59.8% | 2 qtrs — |
| 97 | MANUFACTURERS LIFE INSURANCE COMPANY, THE | 6.9K +6.9K (+100.0%) | 285.7K +285.7K (+100.0%) | 0.02% +0.015 pp | 0.00% +0.000 pp | USD41.43 +0.0% | 1 qtrs NEW |
| 98 | VIRTUS INVESTMENT ADVISERS, INC. | 6.8K -1.6K (-18.5%) | 283.6K +65.9K (+30.3%) | 0.02% -0.004 pp | 0.08% +0.015 pp | USD14.64 +183.0% | 3 qtrs — |
| 99 | NEW YORK STATE COMMON RETIREMENT FUND | 6.7K +— (+0.0%) | 277.6K +103.9K (+59.8%) | 0.01% -0.001 pp | 0.00% +0.000 pp | USD20.81 +99.1% | 4 qtrs — |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
Held by 84 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | State Street SPDR S&P Pharmaceuticals ETF XPH | 1.91% | 9.00M | 0.35% |
| 2 | ALPS Medical Breakthroughs ETF SBIO | 0.86% | 1.84M | 0.50% |
| 3 | Virtus Biotech Clinical Trials ETF BBC | 0.78% | 450.3K | 0.65% |
| 4 | Direxion Daily Pharmaceutical & Medical Bull 3X ETF PILL | 0.40% | 92.5K | 1.22% |
| 5 | iShares Micro-Cap ETF IWC | 0.24% | 3.63M | 0.60% |
| 6 | iShares U.S. Pharmaceuticals ETF IHE | 0.19% | 2.59M | 0.38% |
| 7 | Invesco NASDAQ Biotech UCITS ETF SBIO.L | 0.12% | 538.7K | 0.40% |
| 8 | Invesco Nasdaq Biotechnology ETF IBBQ | 0.12% | 86.9K | 0.19% |
| 9 | iShares Nasdaq US Biotechnology UCITS ETF BTEE.L | 0.12% | 85.2K | 0.35% |
| 10 | iShares Nasdaq US Biotechnology UCITS ETF BTEC.L | 0.12% | 1.27M | 0.35% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.42
Bearish
Ratio by volume
0.55
Neutral
Buys
5
Sells
12
Shares acquired
39.3K
Shares disposed
71.7K
Cash buys
—
Cash sales
6.00
Net activity
-32,422
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-05-04 | HOMCY CHARLES J | Director | G-Gift | D | Common Stock | 7,422 | 0.00 | — | 31,113 | D | ↗ |
| 2026-05-04 | Dandekar Atul | Officer | M-Exempt | D | Stock Option (Right to Buy) | 5,985 | 10.42 | 62.4K | 27,725 | D | ↗ |
| 2026-04-29 | Dandekar Atul | Officer | M-Exempt | D | Stock Option (Right to Buy) | 7,500 | 10.42 | 78.2K | 44,143 | D | ↗ |
| 2026-04-01 | Bernstein Harold | Officer | S-Sale | D | Common Stock | 300 | 31.07 | 9.3K | 0 | D | ↗ |
| 2026-04-01 | Bachrodt Amy | Officer | S-Sale | D | Common Stock | 300 | 30.34 | 9.1K | 12,965 | D | ↗ |
| 2026-03-30 | Dandekar Atul | Officer | M-Exempt | A | Common Stock | 7,500 | 10.42 | 78.2K | 18,003 | D | ↗ |
| 2026-03-27 | Kumar Neil | Director | A-Award | A | Stock Option (Right to Buy) | 33,417 | 30.38 | 1.02M | 33,417 | D | ↗ |
| 2026-03-20 | Bernstein Harold | Officer | M-Exempt | D | Stock Option (Right to Buy) | 15,000 | 10.42 | 156.3K | 252,407 | D | ↗ |
| 2026-03-10 | Bernstein Harold | Officer | M-Exempt | A | Common Stock | 30,000 | 10.42 | 312.6K | 30,000 | D | ↗ |
| 2026-03-02 | Courtney Phillips | Officer | A-Award | A | Stock Option (Right to Buy) | 32,000 | 45.61 | 1.46M | 32,000 | D | ↗ |
| 2026-03-02 | Coloma Jason V | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 150,000 | 45.61 | 6.84M | 150,000 | D | ↗ |
| 2026-02-02 | Bernstein Harold | Officer | S-Sale | D | Common Stock | 100 | 47.23 | 4.7K | 0 | D | ↗ |
| 2026-02-02 | Bachrodt Amy | Officer | S-Sale | D | Common Stock | 4,064 | 46.03 | 187.1K | 13,701 | D | ↗ |
| 2026-01-29 | Dandekar Atul | Officer | S-Sale | D | Common Stock | 1,200 | 43.18 | 51.8K | 16,803 | D | ↗ |
| 2026-01-22 | Bachrodt Amy | Officer | M-Exempt | A | Common Stock | 2,503 | 10.42 | 26.1K | 17,965 | D | ↗ |
| 2026-01-07 | Sohn Catherine A. | Director | M-Exempt | A | Common Stock | 3,281 | 10.42 | 34.2K | 26,920 | D | ↗ |
| 2026-01-07 | Bernstein Harold | Officer | M-Exempt | A | Common Stock | 25,156 | 10.42 | 262.1K | 25,156 | D | ↗ |
| 2026-01-06 | Sohn Catherine A. | Director | M-Exempt | D | Stock Option (Right to Buy) | 2,493 | 10.42 | 26.0K | 3,211 | D | ↗ |
| 2026-01-05 | Bernstein Harold | Officer | M-Exempt | D | Stock Option (Right to Buy) | 412 | 10.42 | 4.3K | 337,563 | D | ↗ |
| 2026-01-02 | Bernstein Harold | Officer | S-Sale | D | Common Stock | 4,432 | 40.43 | 179.2K | 0 | D | ↗ |
| 2026-01-02 | Bachrodt Amy | Officer | M-Exempt | A | Common Stock | 204 | 10.42 | 2.1K | 13,169 | D | ↗ |
| 2025-12-30 | Dandekar Atul | Officer | M-Exempt | A | Common Stock | 100 | 10.42 | 1.0K | 10,603 | D | ↗ |
| 2025-12-30 | Bachrodt Amy | Officer | M-Exempt | A | Common Stock | 2,605 | 10.42 | 27.1K | 17,965 | D | ↗ |
| 2025-12-29 | Dandekar Atul | Officer | S-Sale | D | Common Stock | 6,035 | 41.13 | 248.2K | 10,503 | D | ↗ |
| 2025-12-29 | Bernstein Harold | Officer | S-Sale | D | Common Stock | 17,200 | 40.93 | 703.9K | 0 | D | ↗ |
| 2025-12-29 | Bachrodt Amy | Officer | M-Exempt | D | Stock Option (Right to Buy) | 124 | 10.42 | 1.3K | 2,396 | D | ↗ |
| 2025-11-19 | HOMCY CHARLES J | Director | J-Other | A | Common Stock | 1,489 | 0.00 | — | 31,113 | D | ↗ |
| 2025-11-04 | Third Rock Ventures IV, L.P. | 10% Owner | J-Other | D | Common Stock | 1,600,000 | 0.00 | — | 4,473,958 | D | ↗ |
| 2025-10-23 | HOMCY CHARLES J | Director | G-Gift | D | Common Stock | 28,423 | 0.00 | — | 29,624 | D | ↗ |
| 2025-10-06 | Hoppenot Herve | Director | A-Award | A | Stock Option (Right to Buy) | 36,000 | 27.52 | 990.7K | 36,000 | D | ↗ |
| 2025-09-22 | Sohn Catherine A. | Director | A-Award | A | Stock Option (Right to Buy) | 18,000 | 23.67 | 426.1K | 18,000 | D | ↗ |
| 2025-09-22 | SPIEGELMAN DANIEL K | Director | A-Award | A | Stock Option (Right to Buy) | 18,000 | 23.67 | 426.1K | 18,000 | D | ↗ |
| 2025-09-22 | SCHELLER RICHARD H | Director | A-Award | A | Stock Option (Right to Buy) | 18,000 | 23.67 | 426.1K | 18,000 | D | ↗ |
| 2025-09-22 | Lim Jonathan E | Director | A-Award | A | Stock Option (Right to Buy) | 18,000 | 23.67 | 426.1K | 18,000 | D | ↗ |
| 2025-09-22 | Kathiresan Sekar | Director | A-Award | A | Stock Option (Right to Buy) | 18,000 | 23.67 | 426.1K | 18,000 | D | ↗ |
| 2025-09-22 | HOMCY CHARLES J | Director | A-Award | A | Stock Option (Right to Buy) | 18,000 | 23.67 | 426.1K | 18,000 | D | ↗ |
| 2025-09-22 | Exter Neil | Director | A-Award | A | Stock Option (Right to Buy) | 18,000 | 23.67 | 426.1K | 18,000 | D | ↗ |
| 2025-09-22 | Dandekar Atul | Officer | A-Award | A | Restricted Stock Units | 25,000 | 0.00 | — | 25,000 | D | ↗ |
| 2025-09-22 | Courtney Phillips | Officer | A-Award | A | Restricted Stock Units | 22,000 | 0.00 | — | 22,000 | D | ↗ |
| 2025-09-22 | Coloma Jason V | Director / Officer | A-Award | A | Restricted Stock Units | 100,000 | 0.00 | — | 100,000 | D | ↗ |
| 2025-09-22 | Bernstein Harold | Officer | A-Award | A | Restricted Stock Units | 40,000 | 0.00 | — | 40,000 | D | ↗ |
| 2025-09-22 | Bachrodt Amy | Officer | A-Award | A | Restricted Stock Units | 22,000 | 0.00 | — | 22,000 | D | ↗ |
| 2025-09-22 | Andrews Nancy C | Director | A-Award | A | Stock Option (Right to Buy) | 18,000 | 23.67 | 426.1K | 18,000 | D | ↗ |
| 2025-09-15 | SCHELLER RICHARD H | Director | S-Sale | D | Common Stock | 20,744 | 22.37 | 464.0K | 0 | D | ↗ |
| 2025-09-02 | Tahir Misbah | Officer | A-Award | A | Stock Option (Right to Buy) | 325,000 | 15.32 | 4.98M | 325,000 | D | ↗ |
| 2025-08-17 | Exter Neil | Director | A-Award | A | Stock Option (Right to Buy) | 16,000 | 13.35 | 213.6K | 16,000 | D | ↗ |
Executive team
Top executives
Shares Outstanding
55.25M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2025 | Misbah Tahir Chief Financial Officer | 164.8K | 50.0K | — | 3.66M | 86.7K | 3.5K | 3.96M | 92.31% | ↗ |
| 2 | 2025 | Jason Coloma, Ph.D. Chief Executive Officer | 629.2K | — | 2.37M | — | 457.6K | 4.5K | 3.46M | 68.44% | ↗ |
| 3 | 2025 | Harold Bernstein, M.D., Ph.D. President, Research and Development and Chief Medical Officer | 548.3K | — | 946.8K | — | 321.8K | 4.5K | 1.82M | 51.98% | ↗ |
| 4 | 2024 | Jason Coloma, Ph.D. Chief Executive Officer | 527.3K | — | — | 5.02M | 280.5K | 4.5K | 5.84M | 86.08% | ↗ |
| 5 | 2024 | Harold Bernstein, M.D., Ph.D. President, Research and Development and Chief Medical Officer | 526.7K | — | — | 1.63M | 233.0K | 4.5K | 2.40M | 68.14% | ↗ |
CEO compensation breakdown
Proxy statements
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Jason V. Coloma | Chief Executive Officer & Director | 1M | — |
| Harold S. Bernstein | President of Research & Development and Chief Medical Officer | 874.6K | — |
| Courtney J. Phillips | General Counsel & Corporate Secretary | 354.8K | female |
| Misbah Tahir | Chief Financial Officer | 304.9K | male |
| Matt Krause | Senior Vice President of Human Resources | — | male |
| Nazila Habibizad | Senior Vice President of Technical Operations & Supply Chain | — | female |
| Susan Limb | Senior Vice President of Clinical Development | — | female |
| Vipin Vijayakumar | Vice President of R&D Infrastructure and Operations | — | male |
| Amy Bachrodt | Senior Vice President of Finance | — | female |
| Winston Tse | Senior Vice President of Drug Discovery | — | male |
| Andrew Good | VP & Corporate Controller | — | male |
| Atul Dandekar | Chief Strategy & Business Officer | — | male |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for MAZE
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
